Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -276.21% is 163% below its 5-year average of -105.01%, around the middle of its 5-year range (-677.10%–-25.69%).
As of the fiscal period ended Tuesday, June 30, 2026. 73.47% below its 12-month average of -159.23%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q1 FY2027 (2026-06-30): -276.21%.
RETURN ON EQUITY (ROE)
-276.21%
RETURN ON EQUITY (ROE) AVG TTM
-159.23%
RETURN ON EQUITY (ROE) AVG 3Y
-79.71%
RETURN ON EQUITY (ROE) AVG 5Y
-105.01%
RETURN ON EQUITY (ROE) AVG 10Y
-211.99%
RETURN ON EQUITY (ROE) AVG 15Y
-211.99%
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-73.47%
CURRENT VS 3Y AVG
-246.54%
CURRENT VS 5Y AVG
-163.03%
CURRENT VS 10Y AVG
-30.29%
CURRENT VS 15Y AVG
-30.29%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-557.50%
vs the sector median at left
VistaGen Therapeutics, Inc.
Market Cap
$11.12M
Return on Equity (ROE)
-276.21%
TTM Avg
-159.23%
3Y Avg
-79.71%
5Y Avg
-105.01%
Market Cap
$11.08M
Return on Equity (ROE)
-65.18%
TTM Avg
-26.62%
3Y Avg
-94.28%
5Y Avg
-90.35%
Market Cap
$11.02M
Return on Equity (ROE)
-177.35%
TTM Avg
-89.62%
3Y Avg
-75.99%
5Y Avg
-59.80%
Market Cap
$11.00M
Return on Equity (ROE)
N/A
TTM Avg
-43.97%
3Y Avg
-160.70%
5Y Avg
-188.29%
Market Cap
$10.94M
Return on Equity (ROE)
-477.54%
TTM Avg
-207.60%
3Y Avg
64.51%
5Y Avg
-22.91%
Market Cap
$11.36M
Return on Equity (ROE)
-506.63%
TTM Avg
-300.20%
3Y Avg
-300.20%
5Y Avg
-300.20%
Market Cap
$10.86M
Return on Equity (ROE)
-214.92%
TTM Avg
-46.13%
3Y Avg
-156.76%
5Y Avg
-652.77%
Market Cap
$10.83M
Return on Equity (ROE)
N/A
TTM Avg
-22.56%
3Y Avg
-244.57%
5Y Avg
3710.91%
Market Cap
$11.55M
Return on Equity (ROE)
-102.40%
TTM Avg
-97.28%
3Y Avg
-110.13%
5Y Avg
-94.77%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| VistaGen Therapeutics, Inc. (VTGN) | $11.12M | -276.21% | -159.23% | -79.71% | -105.01% |
| Kiora Pharmaceuticals, Inc. (KPRX)vs › | $11.08M | -65.18% | -26.62% | -94.28% | -90.35% |
| Lisata Therapeutics, Inc. (LSTA)vs › | $11.02M | -177.35% | -89.62% | -75.99% | -59.80% |
| CytoMed Therapeutics Limited (GDTC)vs › | $11.00M | N/A | -43.97% | -160.70% | -188.29% |
| Cerenome, Inc. (CNSY)vs › | $10.94M | -477.54% | -207.60% | 64.51% | -22.91% |
| Caring Brands, Inc. (CABR)vs › | $11.36M | -506.63% | -300.20% | -300.20% | -300.20% |
| BioVie Inc. (BIVI)vs › | $10.86M | -214.92% | -46.13% | -156.76% | -652.77% |
| Polyrizon Ltd. (PLRZ)vs › | $10.83M | N/A | -22.56% | -244.57% | 3710.91% |
| Phio Pharmaceuticals Corp. (PHIO)vs › | $11.55M | -102.40% | -97.28% | -110.13% | -94.77% |
| Pluri Inc. (PLUR)vs › | $10.68M | N/A | 216.74% | -5384.23% | -3626.91% |
ROE
-276.2%
ROA
-189.2%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -276.21% |
| 2026-03-31 | -196.19% |
| 2025-12-31 | -131.67% |
| 2025-09-30 | -93.82% |
| 2025-06-30 | -98.26% |
| 2025-03-31 | -73.05% |
| 2024-12-31 | -58.31% |
| 2024-09-30 | -42.56% |
| 2024-06-30 | -31.67% |
| 2024-03-31 | -25.69% |
| 2023-12-31 | -26.01% |
| 2023-09-30 | -99.53% |
| 2023-06-30 | -677.10% |
| 2023-03-31 | -490.46% |
| 2022-12-31 | -308.15% |
| 2022-09-30 | -217.81% |
| 2022-06-30 | -129.84% |
| 2022-03-31 | -73.80% |
| 2021-12-31 | -46.62% |
| 2021-09-30 | -39.73% |
| 2021-06-30 | -26.34% |
| 2019-03-31 | -347.55% |
| 2018-09-30 | -469.60% |
| 2018-06-30 | -505.79% |
| 2018-03-31 | -207.41% |
| 2017-12-31 | -124.88% |
| 2016-12-31 | -626.15% |
| 2016-09-30 | -384.54% |
| 2016-06-30 | -319.08% |
| 2010-06-30 | -788.70% |
| 2008-12-31 | -80.72% |
